-
Miranda Lambert Leads North Texans with Seven Grammy Nominations for 2027
-
DiDi Advances Robotaxi Operations in China with New R2 Vehicle and Expanded Safety Infrastructure
-
Smart Car Seats Tested: Do Sensors and Apps Actually Improve Safety?
-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
NexCore and MetLife Investment Management Launch $1.3 Billion Senior Living Co-Investment Venture
-
Galway Metals Intersects 1.8 g/t Gold Over 25.0 Metres and 0.7 g/t Gold Over 66.0 Metres at Clarence Stream
-
RuffleButts + RuggedButts Featured in Hasbro's 2026 Holiday Gift Guide
-
KIDZ AI Announces Strategic Collaboration with Synestria to Optimize AI Infrastructure Performance
-
Brightline Interactive and TruWeather Solutions Sign MOU to Bring Weather Data into SpatialCore Physical AI Platform
-
Avino Announces Key Technical Appointment
-
HippoFi Achieves OTCID Market Designation, Opening a New Chapter of Commercial Growth
-
Gabriel Resources Provides Corporate and Financing Update
-
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
-
Pivotree Announces Third Quarter 2026 Results
-
Ur-Energy Commences Baseline Study Fieldwork; Nears Completion of Technical Report at Lost Soldier Uranium Project, Wyoming
-
ImageWorks Display Advances Whole-Store Solutions with a Re-Imagined Planniq Strong and Planniq Chill
-
Razavi Law Group Partners with Chapman University to Prepare the Next Generation of Attorneys
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
How to Turn Your Garage into Usable Living Space
-
Glidewell Opens Applications for 2027 Guiding Leaders Cohorts in California and North Carolina
-
The Next Healthcare Story Worth Telling May Be About Someone You Know
-
NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox (Monkeypox)
-
Atlas Signal Initiates Coverage of High Roller Technologies: ROLR(TM) Prediction-Markets Platform Goes Live on iPhone for U.S. Customers
-
Join Nord Precious Metals' Live Investor Webinar: Advancing Silver Production and High-Grade Exploration in Ontario
-
Executing Our Plan, Increasing Equity and Reducing Liabilities in Order to Build Long-Term Value
-
Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment
-
Nexscient Reports Third Quarter 2026 Results; Revenue Rises Sequentially as Gross Margin Expands to Over 40%
-
Viking Global Technologies Announces Expansion of Grid Protection Technology Pilot with Another Major U.S. Electric Utility
-
TRNR Reports Record Q3 2026 Results, Driven by 66% Revenue Growth; M&A Pipeline Grows Significantly
-
Pinnacle Food Group Limited Achieves Laboratory-Scale Astaxanthin Extraction in Haematococcus pluvialis Program
-
FaZe Esports, a GameSquare Company, Wins Rainbow Six Championship at Osaka Major
-
Waste Energy to Host Shareholder Update Today at 4:30 PM EST; Management to Discuss WE #1 Commissioning, Revenue Opportunities and Growth Strategy
-
Klique Joins Lenovo AI Innovators, Bringing Its Enterprise AI Control Plane to Lenovo Hybrid AI Factory
-
Miami Allstars FC have Applied to Compete in the Women's Premier Soccer League, with the Club Targeting a 2027 or 2028 Debut in North Miami, Florida
-
Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
-
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital
-
Tectonic Metals Completes Record Drill Program at Flat, Advances Five Pillars of Growth Toward Major 2027 Milestones
-
BioLargo Reports Third Quarter 2026 Results, Forecasting Commercial Breakout in 2027
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
VANCOUVER, BC / ACCESS Newswire / August 5, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE: BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery technologies, is pleased to announce significant progress in its global patent portfolio. The Company has received formal communications from both the European Patent Office (EPO) and the Eurasian Patent Organization (EAPO), confirming that the core claims of its patent application covering its proprietary sublingual Cladribine thin-film formulation have been accepted, with full grants anticipated in the near future. The patent further covers all applications of chemotherapy drugs in an oral dissolvable delivery system for the treatment of autoimmune neurological diseases.
Advancing Toward Formal Patent Grant
European Patent Office (EPO): The EPO has issued an Office Action with the intention to grant for BioNxt's key patent application. This confirmation signifies that all core claims have met the European requirements for novelty, inventive step, and industrial applicability. Only minor formal amendments were requested, which the Company has already addressed. The next Office Action is expected within the coming weeks.
Eurasian Patent Organization (EAPO): The EAPO, covering eight member countries across Eastern Europe and Central Asia, has issued a formal notice that BioNxt's patent application has likewise been accepted. Minor language modifications were required and have been promptly submitted. The Company anticipates a full patent grant across all member states in the near term.
Global Patent Strategy and Expansion
BioNxt previously filed an international patent application under the Patent Cooperation Treaty (PCT) to establish a coordinated framework for securing patent protection for its sublingual Cladribine thin-film technology and future products in multiple key markets. The Company has entered the national phase of this application in major pharmaceutical jurisdictions, including the United States, Canada, Japan, Australia, and New Zealand.
These national phase applications are currently progressing through local examination procedures. Patent protection in these regions will support BioNxt's long-term strategy for global commercialization, regulatory alignment, and regional partnership development.
Protecting Innovation in Multiple Sclerosis (MS) Treatment
The patents under review are designed to protect a family of products, including BioNxt's Cladribine-based thin-film formulation, developed for the treatment of relapsing-remitting multiple sclerosis (RRMS). The platform uses sublingual administration to optimize drug absorption, improve patient compliance, and avoid first-pass hepatic metabolism, offering a patient-friendly alternative to injectable or conventional oral therapies.
Patent protections include composition of the sublingual film, methods of administration and dosage, use for treating autoimmune diseases, and scalable manufacturing processes.
"Securing intellectual property rights in both Europe and Eurasia marks a critical step forward for our Cladribine program and sublingual delivery platform," said Hugh Rogers, CEO of BioNxt Solutions. "These patents represent significant commercial value by protecting a high-potential product, enabling regional exclusivity, and enhancing our ability to generate future licensing and partnership revenue."
Next Milestones in Patent Issuance and Product Advancement
BioNxt expects formal grant notices and publication from both the EPO and EAPO shortly. In parallel, the Company is preparing for GMP manufacturing and a human bioequivalence clinical study in Europe to support regulatory filings and commercialization. Further updates will be provided as additional national patent offices complete their evaluations.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumors while reducing side effects.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: [email protected]
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities laws (collectively, "forward-looking information"). Forward-looking information includes, but is not limited to, statements regarding the anticipated grant and scope of European and Eurasian patent rights; the Company's plans for additional international patent filings; the development, clinical evaluation, and commercialization of the Company's Cladribine thin-film (BNT23001) for multiple sclerosis; the strategic importance of intellectual property; the timing and outcome of regulatory processes; and the potential expansion of BioNxt's sublingual drug delivery platform to other therapeutic areas.
Forward-looking information is based on management's reasonable assumptions, expectations, estimates, and projections as of the date of this press release. These statements are subject to known and unknown risks, uncertainties, and other factors-many of which are beyond the Company's control-that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, but are not limited to: patent examination and prosecution outcomes; changes in regulatory or legal frameworks; clinical trial results; scalability of manufacturing processes; strategic partnership risks; and broader economic, financial, or geopolitical conditions.
Readers are cautioned not to place undue reliance on forward-looking information. Although the Company believes that the expectations and assumptions reflected in such statements are reasonable, there can be no assurance that they will prove to be correct. Except as required by applicable securities laws, BioNxt undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
F.Ramirez--AT